Podcast Center
Video Center
Webcasts
Resource Center
Events
January 08, 2018 at 05:37 AM
Pfizer Inc.’s decision to stop research and development into new brain science drugs, including its work in Alzheimer’s and Parkinson’s diseases, will lead to about 300 job cuts.
The move to end the neuroscience-discovery program followed an internal review, the New York-based drugmaker said in an emailed statement.
The job reductions will primarily affect employees at facilities in Cambridge and Andover in Massachusetts, as well as Groton, Connecticut.
Pfizer said it will continue its support of tanezumab, a late-stage pain treatment in development with Eli Lilly & Co., and the fibromyalgia drug Lyrica, as well as research into neurological drugs for rare diseases.
The company also plans to soon start a venture fund committed to brain science.
